◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › GRAL

GRAIL, Inc. (GRAL) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Diagnostics & Research · DATA UPDATED 2026-07-09

GRAIL, Inc. (GRAL) operates in the Diagnostics & Research industry and is headquartered in Menlo Park, United States with about 910 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, GRAL reported $147M in revenue and ($408M) in net income.

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.

Interactive charts & full statements → Open the GRAL valuation workbench →

GRAL Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$147M$126M$93M$56M
Gross Profit($63M)($78M)($96M)($116M)
Operating Income (EBIT)($534M)($768M)($797M)($742M)
Net Income($408M)($2.0B)($1.5B)($5.4B)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GRAL Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$41M$44M$36M$36M$32M
Gross Profit($14M)($11M)($14M)($18M)($20M)
Operating Income (EBIT)($136M)($124M)($125M)($131M)($154M)
Net Income($93M)($99M)($89M)($114M)($106M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GRAL Free Cash Flow History

GRAL Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-31
Total Assets$2.9B$3.0B$3.9B$4.9B
Total Liabilities$344M$480M$268M$292M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GRAL viewer.

Other Companies in Diagnostics & Research

← GRABAll stocksGRAN →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.